Cargando…
Development of a Deimmunized Bispecific Immunotoxin dDT2219 against B-Cell Malignancies
Diphtheria toxin (DT) related targeted toxins are effective in cancer treatment, but efficacy diminishes in time because of their immunogenic potential and/or former vaccinations. In order to overcome this limitation for DT2219, a promising bispecific targeted toxin which targets CD19 and CD22, we d...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5793119/ https://www.ncbi.nlm.nih.gov/pubmed/29316610 http://dx.doi.org/10.3390/toxins10010032 |
_version_ | 1783296882024382464 |
---|---|
author | Schmohl, Joerg U. Todhunter, Deborah Taras, Elizabeth Bachanova, Veronika Vallera, Daniel A. |
author_facet | Schmohl, Joerg U. Todhunter, Deborah Taras, Elizabeth Bachanova, Veronika Vallera, Daniel A. |
author_sort | Schmohl, Joerg U. |
collection | PubMed |
description | Diphtheria toxin (DT) related targeted toxins are effective in cancer treatment, but efficacy diminishes in time because of their immunogenic potential and/or former vaccinations. In order to overcome this limitation for DT2219, a promising bispecific targeted toxin which targets CD19 and CD22, we deimmunized the DT moiety, and thereby developed an exciting improved drug (dDT2219) which still has the potential to sufficiently target B-cell malignancies but also limits clearance because of its reduced immunogenicity. The DT moiety was modified by inducing point mutations in prominent positions on the molecular surface. The new engineered dDT2219 was tested for activity, efficacy, and specificity using functional assays, proliferation assays, and flow cytometry. Furthermore, 12 samples of Chronic Lymphatic Leukemia (CLL) patients were used to assess binding. Immunogenicity was determined using a BALB/c mouse model. dDT2219 was efficient and specific against B-cell malignancies such as Bukitt-Lymphoma cell lines Daudi and Raji. dDT2219 showed specific binding on targets and on CLL samples. Intraperitoneal vaccination of immune competent mice showed that even after multiple administrations with increasing doses, induction of neutralizing antibodies was significantly lower in the dDT2219 treated animal group. The new dDT2219 combines potent anti-tumor cell activity with a reduced immunogenicity. With regard to the frequent development of neutralizing antibodies after multiple administrations with immunotoxins, dDT2219 shows promise to overcome this limitation and thus might maintain effectiveness even after multiple treatment cycles. |
format | Online Article Text |
id | pubmed-5793119 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-57931192018-02-06 Development of a Deimmunized Bispecific Immunotoxin dDT2219 against B-Cell Malignancies Schmohl, Joerg U. Todhunter, Deborah Taras, Elizabeth Bachanova, Veronika Vallera, Daniel A. Toxins (Basel) Article Diphtheria toxin (DT) related targeted toxins are effective in cancer treatment, but efficacy diminishes in time because of their immunogenic potential and/or former vaccinations. In order to overcome this limitation for DT2219, a promising bispecific targeted toxin which targets CD19 and CD22, we deimmunized the DT moiety, and thereby developed an exciting improved drug (dDT2219) which still has the potential to sufficiently target B-cell malignancies but also limits clearance because of its reduced immunogenicity. The DT moiety was modified by inducing point mutations in prominent positions on the molecular surface. The new engineered dDT2219 was tested for activity, efficacy, and specificity using functional assays, proliferation assays, and flow cytometry. Furthermore, 12 samples of Chronic Lymphatic Leukemia (CLL) patients were used to assess binding. Immunogenicity was determined using a BALB/c mouse model. dDT2219 was efficient and specific against B-cell malignancies such as Bukitt-Lymphoma cell lines Daudi and Raji. dDT2219 showed specific binding on targets and on CLL samples. Intraperitoneal vaccination of immune competent mice showed that even after multiple administrations with increasing doses, induction of neutralizing antibodies was significantly lower in the dDT2219 treated animal group. The new dDT2219 combines potent anti-tumor cell activity with a reduced immunogenicity. With regard to the frequent development of neutralizing antibodies after multiple administrations with immunotoxins, dDT2219 shows promise to overcome this limitation and thus might maintain effectiveness even after multiple treatment cycles. MDPI 2018-01-06 /pmc/articles/PMC5793119/ /pubmed/29316610 http://dx.doi.org/10.3390/toxins10010032 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Schmohl, Joerg U. Todhunter, Deborah Taras, Elizabeth Bachanova, Veronika Vallera, Daniel A. Development of a Deimmunized Bispecific Immunotoxin dDT2219 against B-Cell Malignancies |
title | Development of a Deimmunized Bispecific Immunotoxin dDT2219 against B-Cell Malignancies |
title_full | Development of a Deimmunized Bispecific Immunotoxin dDT2219 against B-Cell Malignancies |
title_fullStr | Development of a Deimmunized Bispecific Immunotoxin dDT2219 against B-Cell Malignancies |
title_full_unstemmed | Development of a Deimmunized Bispecific Immunotoxin dDT2219 against B-Cell Malignancies |
title_short | Development of a Deimmunized Bispecific Immunotoxin dDT2219 against B-Cell Malignancies |
title_sort | development of a deimmunized bispecific immunotoxin ddt2219 against b-cell malignancies |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5793119/ https://www.ncbi.nlm.nih.gov/pubmed/29316610 http://dx.doi.org/10.3390/toxins10010032 |
work_keys_str_mv | AT schmohljoergu developmentofadeimmunizedbispecificimmunotoxinddt2219againstbcellmalignancies AT todhunterdeborah developmentofadeimmunizedbispecificimmunotoxinddt2219againstbcellmalignancies AT taraselizabeth developmentofadeimmunizedbispecificimmunotoxinddt2219againstbcellmalignancies AT bachanovaveronika developmentofadeimmunizedbispecificimmunotoxinddt2219againstbcellmalignancies AT valleradaniela developmentofadeimmunizedbispecificimmunotoxinddt2219againstbcellmalignancies |